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Abstract
Background: Intraocular iris rhabdomyosarcoma is extremely rare, and in the 3 cases reported to date occurred as
the primary site of tumour growth. We report a case of rhabdomyosarcoma of the foot metastasizing to the iris.
Case presentation: An 18-year-old white female was referred to the London Ocular Oncology Service for
management of a metastatic rhabdomyosarcomatous deposit in the iris, a metastasis from alveolar
rhabdomyosarcoma of the foot. She was diagnosed nearly 2 years earlier with the primary sarcoma with extensive
systemic spread and treated by resection of the foot lesion and chemotherapy, and achieved a partial remission.
The left iris deposit was noted while she was receiving systemic chemotherapy, heralding a relapse. However,
anterior uveitis and raised intraocular pressure developed and she was referred to our service for further
management. A left iris secondary rhabdomyosarcoma deposit was noticed and in addition a lacrimal gland mass,
as indicated by ultrasound B scan of the eye and orbit. The patient was treated with external beam radiotherapy to
the globe and orbit, but died 2 months after treatment completion.
Conclusion: Rhabdomyosarcoma of the iris is very rare and was previously documented only as a primary
malignancy in this location. We report that secondary spread to the iris can also occur, in this case as the first sign
of widely disseminated systemic relapse.
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Background
Rhabdomyosarcoma (RMS) is the most common soft tis-
sue sarcoma in the paediatric population [1]. The orbit
is the primary tumour site in 10 % of cases and is rarely
a site for secondary spread from a distant extra-orbital
origin [2]. Intraocular primary RMS of the uvea is yet
another rare presentation of the disease, described only
in a handful of case reports [2]. Herein, we report a
unique case of secondary RMS to the iris, a metastasis
from alveolar RMS of the foot.
Case presentation
An 18-year-old white female was referred to the London
Ocular Oncology Service for management of a metastatic
RMS deposit of the left iris. She was originally diagnosed
by the Oxford Oncology team with metastatic alveolar
RMS 22 months earlier, with the primary in the right
flexor digitorum brevis, with extensive metastatic disease,
including intramuscular deposit to the calf, popliteal fossa
nodes, external inguinal chain, multiple mediastinal nodes
and bilateral lung parenchymal involvement with pleural
effusion. Systemic chemotherapy (ifosfamide, vincristine,
actinomycin and doxorubicin) with surgical resection of
the right foot lesion, followed by maintenance chemother-
apy achieved prolonged disease control.
Fourteen months after diagnosis of the metastatic RMS
she noticed a change in the left iris colour. Examination
done at the Oxford Eye Hospital indicated an iris mass
(Fig. 1a), and on PET scan, extensive systemic relapse was
detected, including uptake of the primary foot site, pulmon-
ary nodules as well as the left iris. Vincristine, irinotecan
and temozolomide (VIT) were started, to control the recur-
rent disease, including the iris metastasis, which showed
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good response (Fig. 1b). A subsequent on – treatment re-
lapse occurred after 6 cycles of VIT (primary site, lungs and
musculoskeletal). Palliative oral etoposide was commenced
5 months after first intraocular involvement, keeping the
disease under relative control.
After 3 months of palliative oral etoposide, the iris
tumour recurred, with neovascularization (Fig. 1c), anter-
ior uveitis and intraocular pressure of 40 mmHg. She was
treated with topical antihypertensives and steroids and
referred to our service for consideration for radiotherapy.
Visual acuity was 6/6 in the right eye and 6/36 in the left
eye. Intraocular pressures were 14 mmHg RE and
15 mmHg LE. The right eye was entirely normal. The left
eye had a ciliary flush. There were keratic precipitates but
also larger areas of more confluent deposits on the corneal
endothelium, with stromal oedema. An amelanotic multi-
focal vascularised mass was present in the superior and in-
ferior aspect of the iris, occluding most of the iridocorneal
angle. There were no ciliary body or choroidal tumours,
but cupping of the optic disc was noted. B mode ultra-
sound scan (Acuson Sequoia 512, Siemens AG, Munich,
Germany) with a 14 MHz linear B-scan array probe indi-
cated a 1.7 mm elevated iris lesion with irregular anterior
borders (Fig. 1d) and no ciliary body involvement, and in
addition a lacrimal gland mass was noted. The patient was
treated with palliative external beam radiotherapy (20Gy
in 5 fractions) for both presumed intraocular and orbital
metastatic RMS deposits. Treatment was well tolerated
and there was a prompt and sustained clinical benefit. She
died 2 months later (2 years after RMS diagnosis) from
systemic progressive disease.
Discussion
There is a wide range of tumours that occur in the iris.
Metastasis to the iris is infrequent, reported in fewer
than 10 % of intraocular secondary deposits by Shields
et al. and Konstantinidis et al. [3, 4]. In both reports the
most common primary site was breast and lung, and
there were no cases of systemic RMS metastasizing to
the eye; hence the present case is highly unusual.
In another series by Shields and colleagues, the clinical
features of 104 patients with iris metastasis from systemic
Fig. 1 Left eye iris mass at presentation (a), resolved after initial systemic chemotherapy (b). Ocular tumour relapse (arrow) and neovascularization
of the iris (arrowhead) (c), demonstrated also on B mode ultrasound scan (d)
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cancer were reported [5]. The median age was 60 years,
most were white females, the main symptoms were pain
or blurred vision and the main findings were corectopia
and secondary glaucoma. Most tumours were unifocal
and found in the inferior quadrant. In the present case,
the patient was 18 years old when the intraocular mass
was detected; she had no ocular symptoms but inciden-
tally noticed iris heterochromia; the initial iris relapse was
in the superior quadrant and only further relapse occurred
superiorly and inferiorly, causing secondary glaucoma. In
agreement with other reports, metastasis to the iris is a
feature of advanced disseminated cancer with poor life
prognosis [5].
RMS of the iris has been previously described, but is
considered to be an extremely rare occurrence, reported
to date only in 3 patients [6–8]. In all of these cases, the
iris was the primary site of tumour growth. The Table
summarizes the main clinical features found in those
cases and in the present one. The age at presentation of
patients with primary iris RMS was 5 years or younger
and the presenting feature was development of an iris
mass. Definitive treatment in those cases ultimately was
enucleation with no local or systemic sequelae. The
present case differed from the primary iris RMS ones in
nearly all clinical features, but the mode of presentation.
Management and outcome were obviously different.
RMS is classified into 4 histopathological types: embry-
onal, alveolar, botryoid and pleomorphic [2]. Orbital alveo-
lar type is considered less common but more aggressive
than the embryonal type [9]. The relation between the cell
type, incidence and prognosis of intraocular RMS is not
well established, since this is a rare occurrence.
Conclusion
Rhabdomyosarcoma of the iris is rare. Not only can this
tumour develop in the iris as a primary site [10], but we
report that secondary spread to the iris can also occur,
in this case as the first sign of widely disseminated sys-
temic relapse.
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